What is the address of Novo Nordisk Belgium Manufacturing Holding SA?

The registered office of Novo Nordisk Belgium Manufacturing Holding SA is located at Sint Lendriksborre 10, 1120 Brussel.

Is Novo Nordisk Belgium Manufacturing Holding SA still active?

Yes. According to the CBE (15 November 2026) Novo Nordisk Belgium Manufacturing Holding SA is active, legal situation “Normale toestand”, started on 28 April 1995.

Is Novo Nordisk Belgium Manufacturing Holding SA registered on Peppol?

No, Novo Nordisk Belgium Manufacturing Holding SA is currently not registered on the Peppol network.

What is the enterprise number of Novo Nordisk Belgium Manufacturing Holding SA?

The enterprise number of Novo Nordisk Belgium Manufacturing Holding SA is BE0455204073.

Who are the directors of Novo Nordisk Belgium Manufacturing Holding SA?

According to the 2025 annual accounts, the directors of Novo Nordisk Belgium Manufacturing Holding SA are: Ramon CERON, John KUCKELMAN, Erik, Lorin RASMUSSEN, Cengic DZENANA, Andrew FINNEGAN, Geoffroy BECKERS, Sabine CARLINO, Bruno STUTZMANN.

Is Novo Nordisk Belgium Manufacturing Holding SA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 April 1995; 4 annual accounts filed, latest fiscal year 2025; 8 directors known from the annual account.

How much profit did Novo Nordisk Belgium Manufacturing Holding SA make in 2025?

Novo Nordisk Belgium Manufacturing Holding SA recorded a loss after taxes of € 45,687,844 in financial year 2025.

Novo Nordisk Belgium Manufacturing Holding SA (Public Limited)

Q: When was Novo Nordisk Belgium Manufacturing Holding SA founded?

Novo Nordisk Belgium Manufacturing Holding SA was founded on 28 April 1995.

Dossier Novo Nordisk Belgium Manufacturing Holding SA, printed on 15 November 2026 from databakkes.be/en/0455204073/novo-nordisk-belgium-manufacturing-holding-sa. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

Novo Nordisk Belgium Manufacturing Holding SA from Brussel, company number BE0455204073, closed financial year 2025 with a result of € -45.7 million after tax. Compared with financial year 2024, the result moved from € 689,192 to € -45.7 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.

What it is worth Healthy

€ 81.6 million

▼ 36% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -45.7 million

▼ still € 689,192 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 234,848

▲ € 216,378 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -134.4 million.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Taxes

€ 258,224

▲ 3% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year
	2022	2023	2024	2025	Change 2024 → 2025
Profit after taxes	€ -110,255,770 Profit after taxes 2022: € -110,255,770 First fiscal year in the series	€ 421,288 Profit after taxes 2023: € 421,288 ▲ € 110.7 million vs 2022 (€ -110,255,770) Favourable step	€ 689,192 Profit after taxes 2024: € 689,192 ▲ 64% vs 2023 (€ 421,288) Favourable step	€ -45,687,844 Profit after taxes 2025: € -45,687,844 ▼ € 46.4 million vs 2024 (€ 689,192) Unfavourable step	▼ € 46.4 million
Equity	€ 126,172,447 Equity 2022: € 126,172,447 First fiscal year in the series	€ 126,593,734 Equity 2023: € 126,593,734 Unchanged (€ 126,172,447) Favourable step	€ 127,282,927 Equity 2024: € 127,282,927 ▲ 1% vs 2023 (€ 126,593,734) Favourable step	€ 81,595,082 Equity 2025: € 81,595,082 ▼ 36% vs 2024 (€ 127,282,927) Unfavourable step	▼ 36%
Total debts	€ 90,734 Total debts 2022: € 90,734 First fiscal year in the series	€ 153,359 Total debts 2023: € 153,359 ▲ 69% vs 2022 (€ 90,734) Unfavourable step	€ 351,446 Total debts 2024: € 351,446 ▲ 129% vs 2023 (€ 153,359) Unfavourable step	€ 258,224 Total debts 2025: € 258,224 ▼ 27% vs 2024 (€ 351,446) Favourable step	▼ 27%
Cash	€ 122,456 Cash 2022: € 122,456 First fiscal year in the series	€ 19,274,689 Cash 2023: € 19,274,689 ▲ € 19.2 million vs 2022 (€ 122,456) Favourable step	€ 18,471 Cash 2024: € 18,471 ▼ € 19.3 million vs 2023 (€ 19,274,689) Unfavourable step	€ 234,848 Cash 2025: € 234,848 ▲ € 216,378 vs 2024 (€ 18,471) Favourable step	▲ € 216,378
Retained profit	€ -89,863,656 Retained profit 2022: € -89,863,656 First fiscal year in the series	€ -89,442,369 Retained profit 2023: € -89,442,369 Unchanged (€ -89,863,656) Favourable step	€ -88,753,176 Retained profit 2024: € -88,753,176 ▲ € 689,192 vs 2023 (€ -89,442,369) Favourable step	€ -134,441,021 Retained profit 2025: € -134,441,021 ▼ € 45.7 million vs 2024 (€ -88,753,176) Unfavourable step	▼ € 45.7 million
Balance sheet total	€ 126,263,181 Balance sheet total 2022: € 126,263,181 First fiscal year in the series	€ 126,747,093 Balance sheet total 2023: € 126,747,093 Unchanged (€ 126,263,181) Unchanged	€ 127,634,373 Balance sheet total 2024: € 127,634,373 ▲ 1% vs 2023 (€ 126,747,093) Unchanged	€ 81,853,306 Balance sheet total 2025: € 81,853,306 ▼ 36% vs 2024 (€ 127,634,373) Unchanged	▼ 36%

Key figures of Novo Nordisk Belgium Manufacturing Holding SA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

Ask about Novo Nordisk Belgium Manufacturing Holding SA the way you would ask their accountant.

Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.

Connect ChatGPT or Claude for free

ChatGPT
Claude

Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.

What happened to Novo Nordisk Belgium Manufacturing Holding SA?

What happened at Novo Nordisk Belgium Manufacturing Holding SA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2031 John KUCKELMAN stepped down as director. NBB
2031 Erik, Lorin RASMUSSEN stepped down as director. NBB
2031 Cengic DZENANA stepped down as director. NBB
2031 Andrew FINNEGAN stepped down as director. NBB
2031 Geoffroy BECKERS stepped down as director. NBB
2031 Sabine CARLINO stepped down as director. NBB
Jul 31, 2026 New annual accounts for financial year 2025: loss of € 45.7 million (▼ € 46.4 million vs 2024). Source: NBB ↗
2025 Bruno STUTZMANN stepped down as director. NBB

In short

From € 110.3 million loss in 2022 to € 45.7 million loss in 2025.

Paid € 818,003 in corporate taxes since 2022.

Best year ever: 2024, with € 689,192 profit.

Original PDFs at the National Bank ↗

Management

Novo Nordisk A/S 100%

Novo Nordisk Belgium Manufacturing Holding SA

Novo Nordisk Production Belgium SA

The shares are held by Novo Nordisk A/S (100%). It owns Novo Nordisk Production Belgium SA itself.

Directors

According to the 2025 annual accounts

Ramon CERON

Managing director

Also active at: CATALENT BELGIUM

since 2023 · until 2024

John KUCKELMAN

Director

Also active at: Novo Nordisk Production Belgium SA

since 2024 · until 2031

Erik, Lorin RASMUSSEN

Director

Also active at: Novo Nordisk Production Belgium SA

since 2024 · until 2031

Cengic DZENANA

Managing director

since 2025 · until 2031

Andrew FINNEGAN

Director

Also active at: Novo Nordisk Production Belgium SA

since 2024 · until 2031

Geoffroy BECKERS

Managing director

Also active at: Novo Nordisk Production Belgium SA, AM Biologics Filling Brussels

since 2025 · until 2031

Sabine CARLINO

Director

Also active at: Novo Nordisk Production Belgium SA

since 2025 · until 2031

Bruno STUTZMANN

Director

Also active at: CATALENT BELGIUM

since 2024 · until 2025

Shareholders

Novo Nordisk A/S

100%

Participations

Novo Nordisk Production Belgium SA

Establishments

Establishment units

Physical locations of this company

Registered office

Sint Lendriksborre 10

1120 Brussel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Novo Nordisk Production Belgium SA same network

€ 258.6 million revenue · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0455.204.073
VAT number: BE 0455.204.073
Registered office: Sint Lendriksborre 10, 1120 Brussel
Names & denominations: Novo Nordisk Belgium Manufacturing Holding SA
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 28 April 1995
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗

Novo Nordisk Belgium Manufacturing Holding SA

Warning lights

Financials

Ask about Novo Nordisk Belgium Manufacturing Holding SA the way you would ask their accountant.

What happened to Novo Nordisk Belgium Manufacturing Holding SA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions